(^∀^) try Send-An-Email.com send anonymous email free

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

Say and pronounce Dr. Balar On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   Activity of Immunotherapy in the Frontline Setting   Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer   The Future of Bladder Cancer Research   Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer   Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More   PD-L1 Expression in Bladder Cancer   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   Dr. Balar on Mature Clinical Results of KEYNOTE-052 in Urothelial Cancer   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC   FDA Approval of Durvalumab for Bladder Cancer   Durvalumab FDA Approval for Bladder Cancer   The FDA Approval of Atezolizumab in Bladder Cancer   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   FDA Approval of Atezolizumab for Advanced Bladder Cancer   Upfront Use of Immunotherapy for NCSLC   Combination Trials in Advanced Bladder Cancer   Frontline Atezolizumab for Advanced Bladder Cancer   Dr. Konety on Guidelines for the Management of Bladder Cancer   Pembrolizumab in Newly Diagnosed Squamous NSCLC   Bladder Cancer Recurrence Discovered Through New Urine Test   2015 AACR Annual Meeting Highlights   Dr. Balar on PD-L1 Testing for Urothelial Cancer   Immunotherapy Toxicity Management in Bladder Cancer   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer   Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC   FDA Approval of Durvalumab for Advanced Bladder Cancer   Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer   Upfront Immunotherapy for PD-L1+ NSCLC   Bradley C. Leibovich, M.D.: Urologist - Mayo Clinic   Bladder Cancer: Monoclonal Antibodies Under Investigation   Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer   Combined Immunotherapy and Chemotherapy for NSCLC   Upfront Immunotherapy + Chemotherapy for NSCLC   Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer   Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   Upfront Immunotherapy for NSCLC   Dr. Bang on Pembrolizumab for Advanced Gastric Cancer   Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer   FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More   Dr. David Nanus on Atezolizumab for Urothelial Bladder Cancer   Erik P. Castle, M.D.: Urologist - Mayo Clinic   R. Jeffrey Karnes, M.D.: Urologist - Mayo Clinic   Dr. Daneshmand on Blue Light Cystoscopy for Bladder Cancer   Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer   Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer   Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer   Dr. Black on Sequencing of Immunotherapy in Bladder Cancer   Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer   Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer   Immunotherapy for HNSCC   Pembrolizumab in MSI-H CRC Tumors   Bladder Cancer: Real-World Experience With Immunotherapy   Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer   Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer   Dr. Diaz on Response Rates with Pembrolizumab for CRC   Dr. Inman Discusses the Biology of Bladder Cancer   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC   Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer   Efficacy and Safety of Checkpoint Inhibitors in Lung Cancer   Managing Renal Pelvis Transitional Cell Carcinoma   Dr. Yoon on Immunotherapy in Gastric Cancer   Bladder Cancer: Immunotherapy in the Perioperative Setting   Dr. Diaz on Pembrolizumab for CRC   FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More   New Immunotherapy Approved for Metastatic Bladder Cancer   Dr. Machiels on Pembrolizumab in Head and Neck Cancer   Historic Perspective on Bladder Cancer Treatment   Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer   PD-L1 Immunotherapy in Bladder Cancer

Popular Today